ValuEngine lowered shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a buy rating to a hold rating in a research report released on Friday morning, ValuEngine reports.

Several other research analysts also recently weighed in on AMPH. TheStreet upgraded Amphastar Pharmaceuticals from a c rating to a b- rating in a research note on Wednesday, August 7th. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a hold rating to a buy rating and set a $23.00 price target for the company in a research note on Wednesday, July 10th. Wells Fargo & Co set a $29.00 price target on Amphastar Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, June 6th. Finally, BidaskClub downgraded Amphastar Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, September 10th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $24.64.

Shares of NASDAQ:AMPH opened at $20.73 on Friday. The company has a market capitalization of $990.34 million, a PE ratio of 98.71 and a beta of 1.17. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.81 and a quick ratio of 1.83. The business has a fifty day moving average price of $21.38 and a two-hundred day moving average price of $21.02. Amphastar Pharmaceuticals has a 1 year low of $17.71 and a 1 year high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.05. The firm had revenue of $79.00 million during the quarter, compared to the consensus estimate of $78.90 million. Amphastar Pharmaceuticals had a return on equity of 5.52% and a net margin of 16.33%. The business’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.03 EPS. Sell-side analysts anticipate that Amphastar Pharmaceuticals will post 0.15 earnings per share for the current year.

In related news, SVP Yakob Liawatidewi sold 1,515 shares of the stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $21.24, for a total transaction of $32,178.60. Following the sale, the senior vice president now owns 36,670 shares of the company’s stock, valued at approximately $778,870.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Jason B. Shandell sold 7,340 shares of the stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $21.32, for a total value of $156,488.80. Following the sale, the general counsel now directly owns 147,103 shares in the company, valued at approximately $3,136,235.96. The disclosure for this sale can be found here. Insiders have sold a total of 360,094 shares of company stock valued at $7,529,804 in the last quarter. 30.80% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of AMPH. BNP Paribas Arbitrage SA lifted its holdings in Amphastar Pharmaceuticals by 52,407.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,351 shares of the company’s stock worth $150,000 after purchasing an additional 7,337 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Amphastar Pharmaceuticals by 133.4% during the 1st quarter. SG Americas Securities LLC now owns 18,933 shares of the company’s stock worth $387,000 after purchasing an additional 10,821 shares in the last quarter. Rhumbline Advisers lifted its holdings in Amphastar Pharmaceuticals by 2.1% during the 1st quarter. Rhumbline Advisers now owns 106,120 shares of the company’s stock worth $2,168,000 after purchasing an additional 2,177 shares in the last quarter. Comerica Bank lifted its holdings in Amphastar Pharmaceuticals by 2.1% during the 1st quarter. Comerica Bank now owns 34,703 shares of the company’s stock worth $730,000 after purchasing an additional 722 shares in the last quarter. Finally, Texas Permanent School Fund lifted its holdings in Amphastar Pharmaceuticals by 3.8% during the 1st quarter. Texas Permanent School Fund now owns 23,475 shares of the company’s stock worth $480,000 after purchasing an additional 851 shares in the last quarter. 47.27% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Read More: Average Daily Trade Volume – ADTV

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.